- Home
- ANTX vs COYA Comparison
ANTX vs COYA Comparison
Compare ANTX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | COYA |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.4M | 126.6M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANTX | COYA |
|---|---|---|
| Price | $3.96 | $4.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.00 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 3.3M | 113.2K |
| Earning Date | 03-17-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $820.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $1.00 | $3.94 |
| 52 Week High | $6.91 | $7.75 |
Technical Indicators
Market Signals| Indicator | ANTX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 34.49 |
| Support Level | $1.05 | $3.94 |
| Resistance Level | $6.91 | $5.16 |
| Average True Range (ATR) | 0.90 | 0.28 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 49.70 | 7.41 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.